Impact of rare EGFR exon 19 insertion–deletion variants on tyrosine kinase inhibitor efficacy in non-small-cell lung cancer: a 5-year multicenter analysis
First-generation TKIs represent a potential initial option for EGFR 19delins-mutant LUAD. Proactive later-line strategies, including osimertinib and immunotherapy, optimize survival. Subtype-driven management is critical for this rare population.
Authors
- Wanshun Wen (ORCID: https://orcid.org/0009-0004-5356-7163)
- Fanyu Cheng
- Archana Rao (ORCID: https://orcid.org/0000-0002-2112-9992)
- Zhentao Yu (ORCID: https://orcid.org/0000-0002-5785-8492)
- Zixuan Zhao (ORCID: https://orcid.org/0000-0002-1254-1504)
- Jinhe Xu (ORCID: https://orcid.org/0000-0003-2681-9893)
- Ping Zhang (ORCID: https://orcid.org/0000-0001-9163-6191)
- Ming Chen (ORCID: https://orcid.org/0000-0001-5041-9342)
- Ying Chen (ORCID: https://orcid.org/0000-0001-7876-4877)
- Ming Zhang (ORCID: https://orcid.org/0000-0002-1800-9041)
- Wei Zhang (ORCID: https://orcid.org/0000-0002-5467-6263)
Institutions
- Fujian University of Traditional Chinese Medicine (CN)
- Fujian Medical University (CN)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105564
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fujian Medical University